AEM vs AVNT

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

Avient Corporation exhibits a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm safety from distress. While profitability metrics and recent earnings surprises are positive, declining revenue and earnings growth, coupled with a high payout ratio and elevated valuation, constrain long-term appeal. The stock trades above both the Graham Number ($26.67) and intrinsic value estimate ($8.54), suggesting overvaluation on defensive and growth criteria. However, strong short-term price momentum and analyst consensus of 'strong_buy' provide counterbalancing support.